Bone metastases represent a formidable complication in advanced cancer, often resulting in severe pain, skeletal instability and a diminished quality of life. In recent years, significant progress has ...

For more information about Syncromune®, Inc. please visit www.syncromune.com.

ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases? The following represents disclosure information provided by authors of this manuscript. All ...

Dervis, A. (2025) Curative Outcome of Osteosarcoma with Associated Pleural Effusion: A Case Report —Bone Tumor with Pleural ...

The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy ...

Stage 1 osteosarcoma is usually localized and has not spread to nearby lymph nodes or distant organs. Early-stage disease is ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Reply to: “Beyond 1 Month: A Broader Look at the ROBOMET Trial Results” and “ROBOMET Revisited: Is Stereotactic Body Radiotherapy Truly Effective for Painful Bone Metastases?” The following represents ...

Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...

The FDA has approved Osvyrti (denosumab-desu), a biosimilar to Prolia (denosumab), and Jubereq (denosumab-desu), a biosimilar to Xgeva (denosumab).